• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    These Companies Just Dropped Major Growth Catalysts

    7/10/26 12:17:26 PM ET
    $VRAX
    $ENVX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $VRAX alert in real time by email

    DENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution.

    Virax Expands into Southeast Asia Through Exclusive Fosun Diagnostics Partnership

    Virax Biolabs (NASDAQ:VRAX) announced a significant commercial milestone by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The agreement allows immediate purchase-order driven sales of Virax's commercially available ImmuneSelect research-use immune profiling platform while establishing a framework for future expansion into additional products, higher-volume supply arrangements and potential OEM or private-label opportunities.

    Importantly, the agreement focuses on ImmuneSelect, which is already commercially available for research use, and remains separate from ViraxImmune™, the company's clinical-stage diagnostic platform currently progressing through regulatory development. Initial commercialization efforts will target tuberculosis-related research applications in Thailand before broader expansion throughout Southeast Asia. By leveraging Fosun Diagnostics' established commercial infrastructure and regional customer relationships, Virax gains immediate access to one of the world's fastest-growing healthcare markets while advancing its transition toward commercial revenue generation.

    Government Contract Execution Accelerates as Sales Surpass $2.5 Million

    NAPC Defense (OTCID:BLIS) reported more than $2.5 million in gross sales during the first three months under its recently awarded government IDIQ contracts, representing continued execution of its expanding federal contracting platform. Management indicated the results demonstrate progress converting previously awarded contract opportunities into active project execution across multiple government programs.

    The company continues supporting approximately $38.1 million in previously announced subcontract awards while maintaining access to approximately $57.1 billion in combined U.S. Navy and U.S. Air Force IDIQ contract ceilings extending into the next decade. Alongside its government contracting business, NAPC continues advancing commercialization of the CornerShot USA tactical weapons platform and evaluating additional defense technology opportunities. Management previously outlined expectations for approximately $90 million in fiscal 2027 gross revenue, while noting projections remain preliminary and subject to operational and accounting factors.

    Former Apple Manufacturing Executive Joins as Commercial Production Scales

    Enovix (NASDAQ:ENVX) strengthened its executive leadership by appointing former Apple Director of Product Operations Dr. Michael Vyvoda as Chief Operating Officer. Vyvoda previously helped scale AirPods manufacturing into high-volume production and will now oversee Enovix's global manufacturing, supply chain and operations engineering organizations as the company ramps production across facilities in Malaysia and South Korea.

    The appointment follows a period of accelerating commercial progress. During first-quarter 2026, Enovix reported 49% year-over-year revenue growth to $7.6 million, its sixth consecutive quarter of positive gross profit, and an expanded commercial pipeline exceeding $130 million. The company has begun manufacturing silicon-anode batteries for smart eyewear following its first commercial production order while continuing smartphone qualification activities and expanding into drone and defense markets through its MX-1™ battery platform. As production expands across multiple end markets simultaneously, management is placing increased emphasis on manufacturing execution and operational scalability.

    AI Platform Expands with SpaceXAI Integration

    Rocket One announced its acceptance into the SpaceXAI (NASDAQ:SPCX) API program, adding advanced multimodal artificial intelligence capabilities to its growing AI ecosystem. The platform provides access to models supporting coding, reasoning, text, image, video and voice applications, which the company intends to evaluate across software development, engineering design, mission planning, autonomous decision support and intelligent data analysis.

    The integration complements Rocket One's broader strategy of combining advanced AI software with proprietary nanomagnetic and spintronic semiconductor technologies designed for radiation-tolerant, energy-efficient computing environments supporting defense and space applications. While the announcement does not represent a customer contract, it expands the company's technological capabilities as it continues developing infrastructure for next-generation AI, defense and orbital computing markets.

    Strategic AI Investment Targets Recurring Enterprise Software Revenue

    Trident Digital Tech announced a strategic equity investment in Digital Innovations Group, developer of the proprietary IRMA Engine enterprise AI platform. The investment positions Trident as the commercialization partner for Asia-Pacific and Africa while supporting its strategy of building a recurring-revenue enterprise AI business through software licensing, SaaS subscriptions, white-label deployments, implementation services and managed AI solutions.

    Unlike many emerging AI companies, Trident intends to leverage existing government relationships and digital infrastructure platforms already operating across Africa and Asia-Pacific. The company believes integrating enterprise AI into its digital identity, cybersecurity, government technology and digital commerce ecosystems could expand long-term software revenue while increasing customer engagement across sovereign-scale digital transformation initiatives, including previously announced projects in Ghana and other emerging markets.

    Sources

    Virax Biolabs

    • https://www.viraxbiolabs.com



    Fosun Diagnostics / Fosun Pharma

    • https://www.fosunpharma.com



    NAPC Defense

    • https://napcdefense.com
    • https://napcdefense.com/investor-relations-3/
    • https://napcdefense.com/wp-content/uploads/2026/05/NAPC-DEFENSE-WHITE-PAPER-27-May-2026.pdf



    Enovix (NASDAQ:ENVX)

    • https://enovix.com



    Rocket One

    • https://www.prnewswire.com/news-releases/rocket-one-adds-spacexai-api-to-its-ai-technology-stack-advancing-next-generation-space-and-defense-computing-302821387.html



    Trident Digital Tech Holdings

    • https://tridentity.me
    • https://www.irmaengine.ai



    About 24/7 Market News

    In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

    PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is a third-party media provider and the editor of this article may be compensated for providing ongoing BLIS media outreach and other services, which may be considered a potential conflict of interest. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions.

    Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

    For further information, please visit 247marketnews.com

    CONTACT:

    24/7 Market News

    Editor@247marketnews.com

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

    OTCID:BLIS, NASDAQ:VRAX, NASDAQ:ENVX, NASDAQ:SPCX



    Get the next $VRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRAX
    $ENVX

    CompanyDatePrice TargetRatingAnalyst
    Enovix Corporation
    $ENVX
    5/14/2026$7.50 → $7.00Hold
    TD Cowen
    Enovix Corporation
    $ENVX
    5/14/2026$10.00 → $8.00Buy
    Craig Hallum
    Enovix Corporation
    $ENVX
    5/6/2026Neutral → Underweight
    Analyst
    Enovix Corporation
    $ENVX
    3/12/2026$6.00Neutral
    BofA Securities
    Enovix Corporation
    $ENVX
    2/26/2026$15.00 → $7.50Hold
    TD Cowen
    Enovix Corporation
    $ENVX
    7/24/2025$12.00Overweight → Neutral
    Analyst
    Enovix Corporation
    $ENVX
    7/8/2025$7.00 → $15.00Hold
    TD Cowen
    Virax Biolabs Group Limited
    $VRAX
    3/31/2025$3.00Buy
    H.C. Wainwright
    More analyst ratings

    $VRAX
    $ENVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on Enovix with a new price target

    TD Cowen reiterated coverage of Enovix with a rating of Hold and set a new price target of $7.00 from $7.50 previously

    5/14/26 7:59:24 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Craig Hallum reiterated coverage on Enovix with a new price target

    Craig Hallum reiterated coverage of Enovix with a rating of Buy and set a new price target of $8.00 from $10.00 previously

    5/14/26 7:56:34 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Enovix downgraded by Analyst

    Analyst downgraded Enovix from Neutral to Underweight

    5/6/26 7:33:12 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Talluri Rajendra K covered exercise/tax liability with 17,651 shares, decreasing direct ownership by 0.59% to 2,962,673 units (SEC Form 4) to cover taxes

    4 - Enovix Corp (0001828318) (Issuer)

    7/21/26 8:51:08 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Chief Financial Officer Benton Ryan A covered exercise/tax liability with 19,824 shares, decreasing direct ownership by 2% to 894,556 units (SEC Form 4) to satisfy withholding obligation

    4 - Enovix Corp (0001828318) (Issuer)

    7/16/26 8:21:30 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Chief Accounting Officer Truong Kristina covered exercise/tax liability with 1,268 shares, decreasing direct ownership by 0.42% to 304,149 units (SEC Form 4) (tax withholding)

    4 - Enovix Corp (0001828318) (Issuer)

    7/14/26 6:00:24 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    SEC Filings

    View All

    SEC Form 6-K filed by Virax Biolabs Group Limited

    6-K - Virax Biolabs Group Ltd (0001885827) (Filer)

    7/16/26 7:31:36 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by Virax Biolabs Group Limited

    6-K - Virax Biolabs Group Ltd (0001885827) (Filer)

    7/10/26 4:06:52 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Enovix Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Enovix Corp (0001828318) (Filer)

    7/9/26 7:35:21 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

    Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 millionFosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian marketsPreferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheetNasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirementLONDON, July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX)

    7/16/26 7:30:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

    LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos. 333-292241 and 333-275893). The gross p

    7/10/26 4:05:00 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    These Companies Just Dropped Major Growth Catalysts

    DENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. Virax Expands into Southeast Asia Through Exclusive Fosun Diagnostics Partnership Virax Biolabs (NASDAQ:VRAX) announced a significant commercial milestone by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The agreement allows immediate

    7/10/26 12:17:26 PM ET
    $VRAX
    $ENVX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    Financials

    Live finance-specific insights

    View All

    Enovix to Report First Quarter 2026 Financial Results on May 13, 2026

    FREMONT, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Company" or "Enovix"), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today announced it will report financial results for the first quarter on Wednesday, May 13, 2026, after the close of the market. Enovix will hold a live video call at 2:00 PM PT / 5:00 PM ET on May 13, 2026, to discuss the company's recent business updates, commercialization progress, operational milestones, and financial results. To join the call, participants must use the following link to register: https://enovix-q1-2026.open-exchange.net/ This link will also be a

    4/27/26 4:15:00 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Enovix to Release Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    FREMONT, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Company" or "Enovix"), a global high-performance battery company, today announced it will release financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after the close of the market. Enovix will hold a live video call at 2:00 PM PT / 5:00 PM ET on February 25, 2026, to discuss the company's business updates, key milestones, and financial results. To join the call, participants must use the following link to register: https://enovix-q4-2025.open-exchange.net/.  This link will also be available via the Investor Relations section of Enovix's website at https://ir.enovi

    2/11/26 8:30:00 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Enovix Announces December Investor Events

    FREMONT, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Enovix"), a global high-performance battery company, today announced its participation in the following investor events: Canaccord Genuity Fireside Chat with Enovix CEO Dr. Raj Talluri Date: Wednesday, December 10, 2025Webcast recording: available after market close here 11th Annual Jefferies Virtual Battery Tech ConferenceDate: Friday December 12, 2025 The company will discuss various business topics, including its lead smartphone engagement, which was advanced earlier this month by successful shipment of Enovix's latest AI-1TM battery samples to the Enovix lead customer. Interested portfolio managers

    12/9/25 4:15:00 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    Leadership Updates

    Live Leadership Updates

    View All

    Enovix Appoints Former Apple Operations Leader Michael Vyvoda as Chief Operating Officer to Lead Global Manufacturing Ramp

    FREMONT, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Enovix"), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today announced that Dr. Michael Vyvoda, former Director of Product Operations at Apple who helped scale AirPods manufacturing to high-volume production, will join the Company as Chief Operating Officer, effective July 29, 2026. Michael will report to Dr. Raj Talluri, President and CEO, and will assume responsibility for Enovix’s global manufacturing, supply chain and operations engineering organizations as the Company scales to sustained, high-volume production at its Malaysia and

    7/9/26 7:30:00 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Enovix Corporation Appoints Steve Bakos as Senior Vice President of Worldwide Sales to Support Commercial Scale-up and Revenue Growth

    FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Enovix"), a leader in advanced lithium-ion battery technology, today announced the appointment of Steve Bakos as Senior Vice President of Worldwide Sales. He reports to Samira Naraghi, Chief Business Officer in a newly created role. The move comes as Enovix advances toward the commercial launch of its flagship 100% silicon-anode batteries and continues scaling of its silicon-enhanced product line from Korea. The appointment reflects Enovix's transition from technology qualification toward commercial execution across consumer and industrial markets. Bakos is a veteran sales executive with more than 35 ye

    5/5/26 7:45:00 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    Enovix Announces Leadership Transition to Support Manufacturing Scale-Up

    FREMONT, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Enovix Corporation (NASDAQ:ENVX) ("Enovix"), a global high-performance battery company, today announced a leadership transition in its operations organization, including the planned retirement of its Chief Operating Officer, as the company prepares to commence mass production. The transition reflects Enovix's focus on proven, high-volume battery manufacturing leadership as it moves toward sustained production for smartphone, smart eyewear, and defense applications. Enovix expressed its appreciation for Ajay Marathe's leadership and service, including his role in helping establish the company's manufacturing presence at Fab2 in Malaysia. Th

    1/20/26 8:30:00 AM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    $VRAX
    $ENVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Enovix Corporation (Amendment)

    SC 13G/A - Enovix Corp (0001828318) (Subject)

    2/14/24 4:05:49 PM ET
    $ENVX
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Virax Biolabs Group Limited

    SC 13G - Virax Biolabs Group Ltd (0001885827) (Subject)

    2/14/24 3:56:54 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care